Positive CHMP opinion brings us closer to offering WELIREG, a first-in-class HIF-2α inhibitor, to certain patients in the European Union, in order to...
A2A Pharmaceuticals, Inc. ("A2A or "the company"), a clinical-stage pioneering biopharmaceutical company focused on developing innovative cancer therapies,...
Eli Lilly and Company (NYSE: LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen recept...
Matt Boag, Biopharmaceutical Product Marketing Manager at Phenomenex, discusses the transformative innovations shaping plasmid DNA, mRNA, and peptide purif...
In a thought-provoking Q&A with BioPharma BoardRoom, Demaris Mills, President of Integrated DNA Technologies (IDT), discusses the transformative advanc...
In a detailed interview with BioPharma BoardRoom, Kerstin Pohl, Senior Global Marketing Manager for Gene Therapy & Nucleic Acid at SCIEX, delves into t...
Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT0...
Roche (SIX: RO, ROG; OTCQX: RHHBY) that new and updated data from its industry-leading CD20xCD3 T-cell-engaging bispecific antibody programme were presente...
Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody disc...
Eli Lilly and Company (NYSE: LLY) announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent (reversible) Bruton'...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA ® (...
- Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying patholo...
Amarna Therapeutics, (“Amarna” or “the Company”), a privately held biotechnology company specializing in transformative gene therap...
Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis announced that they have entered into an exclusive option and license agreement to discover...
© 2025 Biopharma Boardroom. All Rights Reserved.
